The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
Ghassan K. Abou-Alfa
Consultant or Advisory Role - Exelixis (U)
Research Funding - Exelixis
Ann-Lii Cheng
Consultant or Advisory Role - Exelixis
Tim Meyer
Consultant or Advisory Role - Exelixis
Anthony B. El-Khoueiry
Consultant or Advisory Role - Exelixis (U)
Honoraria - Exelixis
Masafumi Ikeda
Consultant or Advisory Role - Exelixis
Hoo Geun Chun
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis
Sandrine J. Faivre
Honoraria - Exelixis
Research Funding - Exelixis
Junji Furuse
No relevant relationships to disclose
Jennifer J. Knox
No relevant relationships to disclose
Takuji Okusaka
Consultant or Advisory Role - Exelixis
Jerry Ping
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Anne E. Borgman-Hagey
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Robin Kate Kelley
Consultant or Advisory Role - Exelixis (U)
Research Funding - Exelixis